Literature DB >> 33122823

Subtype-selective mechanisms of negative allosteric modulators binding to group I metabotropic glutamate receptors.

Ting-Ting Fu1,2, Gao Tu1,2, Meng Ping1, Guo-Xun Zheng1,2, Feng-Yuan Yang1,2, Jing-Yi Yang1,2, Yang Zhang1,2, Xiao-Jun Yao3, Wei-Wei Xue4, Feng Zhu5,6.   

Abstract

Group I metabotropic glutamate receptors (mGlu1 and mGlu5) are promising targets for multiple psychiatric and neurodegenerative disorders. Understanding the subtype selectivity of mGlu1 and mGlu5 allosteric sites is essential for the rational design of novel modulators with single- or dual-target mechanism of action. In this study, starting from the deposited mGlu1 and mGlu5 crystal structures, we utilized computational modeling approaches integrating docking, molecular dynamics simulation, and efficient post-trajectory analysis to reveal the subtype-selective mechanism of mGlu1 and mGlu5 to 10 diverse drug scaffolds representing known negative allosteric modulators (NAMs) in the literature. The results of modeling identified six pairs of non-conserved residues and four pairs of conserved ones as critical features to distinguish the selective NAMs binding to the corresponding receptors. In addition, nine pairs of residues are beneficial to the development of novel dual-target NAMs of group I metabotropic glutamate receptors. Furthermore, the binding modes of a reported dual-target NAM (VU0467558) in mGlu1 and mGlu5 were predicted to verify the identified residues that play key roles in the receptor selectivity and the dual-target binding. The results of this study can guide rational structure-based design of novel NAMs, and the approach can be generally applicable to characterize the features of selectivity for other G-protein-coupled receptors.
© 2020. CPS and SIMM.

Entities:  

Keywords:  computational modeling; drug selectivity; metabotropic glutamate receptors; negative allosteric modulators; psychiatric and neurodegenerative disorders

Mesh:

Substances:

Year:  2020        PMID: 33122823      PMCID: PMC8285414          DOI: 10.1038/s41401-020-00541-z

Source DB:  PubMed          Journal:  Acta Pharmacol Sin        ISSN: 1671-4083            Impact factor:   7.169


  79 in total

Review 1.  Allosteric modulation of family C G-protein-coupled receptors: from molecular insights to therapeutic perspectives.

Authors:  Stephan Urwyler
Journal:  Pharmacol Rev       Date:  2011-01-12       Impact factor: 25.468

Review 2.  Pharmacology and functions of metabotropic glutamate receptors.

Authors:  P J Conn; J P Pin
Journal:  Annu Rev Pharmacol Toxicol       Date:  1997       Impact factor: 13.820

Review 3.  Metabotropic glutamate receptors as therapeutic targets in Parkinson's disease: An update from the last 5 years of research.

Authors:  Nadhir Litim; Marc Morissette; Thérèse Di Paolo
Journal:  Neuropharmacology       Date:  2016-04-04       Impact factor: 5.250

4.  Structure of class C GPCR metabotropic glutamate receptor 5 transmembrane domain.

Authors:  Andrew S Doré; Krzysztof Okrasa; Jayesh C Patel; Maria Serrano-Vega; Kirstie Bennett; Robert M Cooke; James C Errey; Ali Jazayeri; Samir Khan; Ben Tehan; Malcolm Weir; Giselle R Wiggin; Fiona H Marshall
Journal:  Nature       Date:  2014-07-06       Impact factor: 49.962

Review 5.  Targeting glutamate signalling in depression: progress and prospects.

Authors:  James W Murrough; Chadi G Abdallah; Sanjay J Mathew
Journal:  Nat Rev Drug Discov       Date:  2017-03-17       Impact factor: 84.694

6.  Therapeutic target database update 2018: enriched resource for facilitating bench-to-clinic research of targeted therapeutics.

Authors:  Ying Hong Li; Chun Yan Yu; Xiao Xu Li; Peng Zhang; Jing Tang; Qingxia Yang; Tingting Fu; Xiaoyu Zhang; Xuejiao Cui; Gao Tu; Yang Zhang; Shuang Li; Fengyuan Yang; Qiu Sun; Chu Qin; Xian Zeng; Zhe Chen; Yu Zong Chen; Feng Zhu
Journal:  Nucleic Acids Res       Date:  2018-01-04       Impact factor: 16.971

7.  NOREVA: normalization and evaluation of MS-based metabolomics data.

Authors:  Bo Li; Jing Tang; Qingxia Yang; Shuang Li; Xuejiao Cui; Yinghong Li; Yuzong Chen; Weiwei Xue; Xiaofeng Li; Feng Zhu
Journal:  Nucleic Acids Res       Date:  2017-07-03       Impact factor: 16.971

Review 8.  Targeting metabotropic glutamate receptors for novel treatments of schizophrenia.

Authors:  James Maksymetz; Sean P Moran; P Jeffrey Conn
Journal:  Mol Brain       Date:  2017-04-26       Impact factor: 4.041

9.  An Appraisal of the Influence of the Metabotropic Glutamate 5 (mGlu5) Receptor on Sociability and Anxiety.

Authors:  Arnau Ramos-Prats; Julia Kölldorfer; Elena Paolo; Maximilian Zeidler; Gabriele Schmid; Francesco Ferraguti
Journal:  Front Mol Neurosci       Date:  2019-02-19       Impact factor: 5.639

10.  Structural insights into the activation of metabotropic glutamate receptors.

Authors:  Antoine Koehl; Hongli Hu; Dan Feng; Bingfa Sun; Yan Zhang; Michael J Robertson; Matthew Chu; Tong Sun Kobilka; Toon Laeremans; Jan Steyaert; Jeffrey Tarrasch; Somnath Dutta; Rasmus Fonseca; William I Weis; Jesper M Mathiesen; Georgios Skiniotis; Brian K Kobilka
Journal:  Nature       Date:  2019-01-23       Impact factor: 49.962

View more
  3 in total

Review 1.  Targeting the Type 5 Metabotropic Glutamate Receptor: A Potential Therapeutic Strategy for Neurodegenerative Diseases?

Authors:  Rebecca F Budgett; Geor Bakker; Eugenia Sergeev; Kirstie A Bennett; Sophie J Bradley
Journal:  Front Pharmacol       Date:  2022-05-11       Impact factor: 5.988

2.  VARIDT 2.0: structural variability of drug transporter.

Authors:  Tingting Fu; Fengcheng Li; Yang Zhang; Jiayi Yin; Wenqi Qiu; Xuedong Li; Xingang Liu; Wenwen Xin; Chengzhao Wang; Lushan Yu; Jianqing Gao; Qingchuan Zheng; Su Zeng; Feng Zhu
Journal:  Nucleic Acids Res       Date:  2022-01-07       Impact factor: 16.971

3.  Curcumin inhibits spike protein of new SARS-CoV-2 variant of concern (VOC) Omicron, an in silico study.

Authors:  Anish Nag; Ritesh Banerjee; Subhabrata Paul; Rita Kundu
Journal:  Comput Biol Med       Date:  2022-04-27       Impact factor: 6.698

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.